AdAlta is pioneering the development of innovative therapeutic solutions through its proprietary i-body drug discovery platform, which is designed to target diseases that traditional antibodies cannot effectively address. The i-body technology allows for the creation of smaller, more versatile therapeutic agents that maintain the beneficial properties of antibodies while being significantly more compact. This platform has enabled AdAlta to build a library of over 20 billion i-body compounds, which can be rapidly screened against various disease targets. The company is particularly focused on addressing unmet clinical needs in areas such as fibrosis and immuno-oncology, with its lead asset, AD-214, being a first-in-class product aimed at treating fibrotic diseases.

In addition to its work on fibrosis, AdAlta is also exploring the potential of i-CAR-T cell therapies, which involve reprogramming immune cells to combat solid tumors, and i-PET imaging, a technique that helps assess the effectiveness of immunotherapy in cancer patients. The company’s research extends to various forms of fibrosis affecting critical organs, including the lungs, liver, kidneys, and eyes, highlighting the broad applicability of its i-body technology. By targeting complex disease mechanisms, such as G protein-coupled receptors (GPCRs) and ion channels, AdAlta aims to unlock new therapeutic avenues for conditions that have historically been challenging to treat.

Australia

AdAlta (ASX:1AD) is the pioneer of a novel technology platform that mimics the shape and engineers key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies, for therapeutic intervention in disease.

AdAlta is utilising the power of its i-body technology platform to develop a pipeline of i-bodies (drugs), with an initial focus on treating fibrotic diseases.

AdAlta

Company Details